These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 21411216)
1. [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study]. González-Juanatey JR; Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC Rev Esp Cardiol; 2011 Apr; 64(4):286-94. PubMed ID: 21411216 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey. Strang AC; Kaasjager HA; Basart DC; Stroes ES Neth J Med; 2010 Apr; 68(4):168-74. PubMed ID: 20421658 [TBL] [Abstract][Full Text] [Related]
3. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution. Ferrières J; Bérard E; Crisan O; Bongard V Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240 [TBL] [Abstract][Full Text] [Related]
4. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). da Silva PM; Cardoso SM; Rev Port Cardiol; 2011 Jan; 30(1):47-63. PubMed ID: 21425743 [TBL] [Abstract][Full Text] [Related]
5. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian]. Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165 [TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Lardizabal JA; Deedwania P Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102 [TBL] [Abstract][Full Text] [Related]
7. [Statins in the management of dyslipidemias]. Scheen AJ Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981 [TBL] [Abstract][Full Text] [Related]
8. Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). Silva PM; Cardoso SM; Ferreira AM Clin Exp Hypertens; 2015; 37(2):116-21. PubMed ID: 24785978 [TBL] [Abstract][Full Text] [Related]
9. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217 [TBL] [Abstract][Full Text] [Related]
10. Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Bestehorn K; Smolka W; Pittrow D; Schulte H; Assmann G Curr Med Res Opin; 2010 Dec; 26(12):2833-9. PubMed ID: 21058895 [TBL] [Abstract][Full Text] [Related]
11. The role of statins in managing diabetic dyslipidemia. Toth PP J Fam Pract; 2010 May; 59(5 Suppl):S23-9. PubMed ID: 20544054 [TBL] [Abstract][Full Text] [Related]
12. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Corrao G; Conti V; Merlino L; Catapano AL; Mancia G Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Gitt AK; Jünger C; Smolka W; Bestehorn K Clin Res Cardiol; 2010 Nov; 99(11):723-33. PubMed ID: 20521058 [TBL] [Abstract][Full Text] [Related]
14. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related]
16. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). Drexel H; Chazelle F; Fauer C; Lautsch D; Gitt AK Wien Klin Wochenschr; 2011 Oct; 123(19-20):611-7. PubMed ID: 21947362 [TBL] [Abstract][Full Text] [Related]
17. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Petrella RJ; Merikle E; Jones J Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298 [TBL] [Abstract][Full Text] [Related]
19. Impact of international guidelines on the management of cardiovascular risk factors in diabetic patients with peripheral arterial disease. Margeta C; Giurgea A; Hammer A; Schlager O; Zehetmayer S; Koppensteiner R; Willfort-Ehringer A Int Angiol; 2009 Jun; 28(3):175-80. PubMed ID: 19506537 [TBL] [Abstract][Full Text] [Related]
20. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. Ong HT QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]